SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “alert” to 97000 to receive our instant, reliable and free SMS alerts.

Hello fellow investors / traders,

 

Today's play delivered us decent 6-7% gains on big volume without much volatility. I will continue to monitor and update you if and when I see further upside potential.

Tomorrow I found a chart that I think screams winner. RGBP is the ticker.  

RGBP has a tight level 2, good average daily volume, and as you can see below, a nice looking chart with well defined support and resistance levels.

And while the chart attracted me at first, there is much to be excited about RGBP's fundamentals as well (more on this shortly).

RGBP closed today at $0.056. Its recent 52 week lows is around $0.04, and support appears around $0.05. In contrast its recent highs and very clear long term resistance which has been tested on multiple occasions is at $0.10. 

Based on these support & resistance points, I think RGBP could be an outstanding risk / reward trade opportunity.

From its current level, the chart is showing a potential 77% upside in the near term.

There is more than just a solid looking tradable chart however. This could make a nice longer term trade.

Regen BioPharma Inc. (RGBP) is a publicly traded biotechnology company that seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space, specifically working to develop immunotherapies and cancer stem cell therapies for rapid commercialization. 

The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow.

You can read all about RGBP at their website http://www.regenbiopharmainc.com/

One thing that caught my attention was that RGBP is working a giant in the pharma space, Eli Lilly & Co (NYSE: LLY), a $93 BILLION company listed on the NYSE.

RGBP entered into an agreement with Eli Lilly which allows RGBP to receive compounds from Lilly for drug discovery purposes and allows RGBP to share structural information on compounds of mutual interest.

The agreement also grants to Lilly an option to negotiate an agreement with RGBP including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.

This is huge for RGBP, a tiny biotech with a market cap of less than $10m.

The market for immunotherapy drugs that RGBP is tackling is massive. Currently at around $108 billion it is expected to reach $201 billion by 2021.

I could literally go on and on about RGBP, and the impressive news they've released to the market in recent months, such as the license agreements they have entered into, the patents they have filed for and been granted, and the clinical trials they have been cleared by the FDA to proceed with.

You can read here all of the impressive news RGBP has announced in recent times.


In Summary...

RGBP has plenty of short and longer term potential upside, and we think RGBP could make a excellent short and longer term trade.

The company has been releasing some very impressive news to the market, including working closely with pharma giant Eli Lilly (NYSE: LLY), and these catalysts continue to attract investors attention.

The level 2 is tight, and the average daily volume is good - great for traders.

Get RGBP on your radar now and be ready to trade.